Sugi Predict

Sugi Predict / Targets / PDE11A

PDE11A

Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A · Q9HCR9 · PDE11A on Sugi Atlas →

16,221 patent compounds predicted against PDE11A, 11,711 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL691228 SCHEMBL691228 0.58 13/20
SCHEMBL152335 SCHEMBL152335 0.54 11/20
SCHEMBL152336 SCHEMBL152336 0.54 11/20
SCHEMBL1327741 SCHEMBL1327741 0.76 8/20
SCHEMBL969355 SCHEMBL969355 0.67 8/20
SCHEMBL1327318 SCHEMBL1327318 0.78 7/20
SCHEMBL1327321 SCHEMBL1327321 0.78 7/20
SCHEMBL1327324 SCHEMBL1327324 0.78 7/20
SCHEMBL969642 SCHEMBL969642 0.71 7/20
SCHEMBL971800 SCHEMBL971800 1.00 6/20
SCHEMBL972085 SCHEMBL972085 0.79 6/20
SCHEMBL970666 SCHEMBL970666 0.55 6/20
SCHEMBL968940 SCHEMBL968940 0.53 6/20
SCHEMBL772857 SCHEMBL772857 1.00 5/20
SCHEMBL798735 SCHEMBL798735 0.85 5/20
SCHEMBL773887 SCHEMBL773887 0.84 5/20
SCHEMBL798734 SCHEMBL798734 0.84 5/20
SCHEMBL798393 SCHEMBL798393 0.82 5/20
SCHEMBL798580 SCHEMBL798580 0.78 5/20
SCHEMBL969419 SCHEMBL969419 0.77 5/20

Clinical trials — most relevant to PDE11A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Sildenofil in Persistent Pulmonary Hypertension in Newborns PHASE3UNKNOWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study PHASE2COMPLETED
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Effect of Modulating the nNOS System on Cardiac, Muscular and Cognitive Function in Becker Muscular Dystrophy Patients PHASE2COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT) PHASE2COMPLETED
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction PHASE2COMPLETED
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients PHASE2COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Is Pentoxifylline Able to Improve Olfactory Sensitivity? nanCOMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE11A binder may also engage these)

ProteinNameSimilarity
Q1KKS3 — 1.000 Q1KKS3 →
Q8VID6 — 1.000 Q8VID6 →
P0C1Q2 — 1.000 P0C1Q2 →
B4LVU6 — 0.997 B4LVU6 →
B3LVW5 — 0.995 B3LVW5 →
PDE5A cGMP-specific 3',5'-cyclic phosphodiesterase 0.995 landscape →
Q298P4 — 0.994 Q298P4 →
B3P3K2 — 0.993 B3P3K2 →
B4PSS5 — 0.993 B4PSS5 →
B4K9L4 — 0.993 B4K9L4 →
O77746 — 0.992 O77746 →
O54735 — 0.992 O54735 →
B4HEM4 — 0.992 B4HEM4 →
Q9VFI9 — 0.991 Q9VFI9 →
Q28156 — 0.991 Q28156 →
Q8CG03 — 0.990 Q8CG03 →
P33726 — 0.990 P33726 →
B4NAL6 — 0.989 B4NAL6 →
B4QZU1 — 0.989 B4QZU1 →
P23439 — 0.989 P23439 →
P16586 — 0.988 P16586 →
Q91ZQ1 — 0.988 Q91ZQ1 →
E9Q4S1 — 0.988 E9Q4S1 →
P23440 — 0.987 P23440 →
PDE6A Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha 0.987 landscape →
PDE6B Rod cGMP-specific 3',5'-cyclic phosphodiester 0.987 landscape →
P91119 — 0.987 P91119 →
Q28263 — 0.987 Q28263 →
P11541 — 0.986 P11541 →
P52731 — 0.985 P52731 →